您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > SBP-7455
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
SBP-7455
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
SBP-7455图片
规格:98%
分子量:354.3
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
25mg电议

产品介绍
SBP-7455 是一种有效的、高亲和力和口服活性的双重 ULK1/ULK2 自噬抑制剂,在 ADP-Glo 试验中 IC50 分别为 13 nM 和 476 nM。 SBP-7455 有效抑制 ULK1/2 酶活性,可用于三阴性乳腺癌 (TNBC) 研究。
货号:ajcx24460
CAS:1884222-74-5
分子式:C16H17F3N4O2
分子量:354.3
溶解度:DMF: 30 mg/ml,DMSO: 30 mg/ml,DMSO:PBS (pH 7.2) (1:4): 0.20 mg/ml,Ethanol: 1 mg/ml
纯度:98%
存储:Store at -20°C
库存:现货

Background:

SBP-7455 is a dual inhibitor of unc-51-like autophagy activating kinase 1 (ULK1) and ULK2 (IC50s = 13 and 476 nM, respectively, for the recombinant human enzymes in cell-free assays).1It inhibits increases in autophagic flux and induces apoptosis in serum-deprived MDA-MB-468 breast cancer cells when used at a concentration of 10 µM. SBP-7455 (0.19 µM), alone or in combination with olaparib , reduces the viability of MDA-MB-468 cells.


1.Ren, H., Bakas, N.A., Vamos, M., et al.Design, synthesis, and characterization of an orally active dual-specific ULK1/2 autophagy inhibitor that synergizes with the PARP inhibitor olaparib for the treatment of triple-negative breast cancerJ. Med. Chem.63(23)14609-14625(2020)